Niacinamide (Nicotinamide).

Both feed the same NAD pool, nicotinamide through NAMPT and nicotinamide riboside through NRK phosphorylation. They overlap on one destination rather than adding two.

NMN is the immediate product of the NAMPT step that nicotinamide passes through, so both arrive at NAD by the same salvage route.

Nicotinamide is the salvage precursor the cell rebuilds NAD from, and NAD breakdown by CD38, PARPs and sirtuins releases nicotinamide again. The pair is one cycle.

Nicotinic acid enters NAD synthesis through the Preiss-Handler route while nicotinamide uses salvage, and only nicotinic acid activates the GPR109A receptor that causes flushing. They satisfy the same vitamin requirement but do not do the same extra things.

The kynurenine pathway builds NAD from tryptophan at roughly 60 mg tryptophan per mg of niacin equivalent. Supplied nicotinamide covers that need and leaves tryptophan for protein and serotonin synthesis.

Kynureninase, the step that lets tryptophan continue toward NAD, is a pyridoxal phosphate enzyme. With low B6 that route stalls and dietary nicotinamide carries more of the NAD supply.

Kynurenine 3-monooxygenase needs FAD from riboflavin to move tryptophan along the pathway toward NAD. Poor riboflavin status narrows that route.

The first committed step, tryptophan 2,3-dioxygenase, is a heme enzyme and therefore iron-dependent. Low iron slows entry into the pathway that generates NAD from tryptophan.

Surplus nicotinamide is cleared by nicotinamide N-methyltransferase, which spends a SAM methyl group on each molecule. At higher intakes betaine resupplies the methyl pool that clearance draws down.

Nicotinamide clearance consumes SAM directly through NNMT methylation, producing methylnicotinamide. High nicotinamide intake and SAM therefore pull on the same methyl budget.

Sirtuins need NAD as a co-substrate, which nicotinamide restores, but nicotinamide is also the reaction product and inhibits sirtuins at higher concentrations. So the pairing helps through the NAD pool and works against itself at the enzyme.

Pterostilbene acts on sirtuin signalling, and sirtuins cannot turn over without NAD, which nicotinamide salvage supplies. The same product inhibition that applies to nicotinamide at the enzyme applies here.

Apigenin inhibits CD38, one of the main NAD-consuming enzymes, so less of the pool is broken down while nicotinamide rebuilds it.

Niacinamide raises ceramide and free fatty acid synthesis in the stratum corneum, strengthening the barrier that retinoid use tends to strain. Pairing them is standard practice in retinoid formulas for that reason.

Niacinamide upregulates the enzymes that build stratum corneum ceramides while applied ceramides supply the lipid itself. One drives synthesis, the other supplies the material.

Niacinamide supports barrier lipid synthesis and reduces sebum output, which pairs with azelaic acid's action on keratinisation and pigment transfer. The two act on different steps in the same surface.

CD38 is the dominant NAD-consuming enzyme in many tissues and rises with age, and quercetin inhibits it in cell and animal work. Combining precursor supply with slower consumption is the mechanistic logic. What has been measured is enzyme activity and tissue NAD, not a clinical endpoint in people.

Luteolin is among the flavones reported to inhibit CD38 in laboratory screens, which would slow the breakdown side of NAD turnover. The pairing rationale is the same as for quercetin and rests on the same preclinical layer. No human combination data support it.

Urolithin A is studied for its effect on mitochondrial turnover, while niacinamide feeds the NAD pool those mitochondria depend on for oxidative metabolism. The two act at different points on mitochondrial function. This is a rationale for pairing, not a measured combined effect.

Spermidine is studied through autophagy-related signalling and niacinamide through NAD-dependent sirtuin signalling, two arms of cellular maintenance that overlap in the literature without being the same pathway. Products often carry both on that reasoning. The combination itself is untested in people.

NADH produced from the niacinamide-derived NAD pool donates electrons at complex I, which passes them directly to coenzyme Q10. The two sit consecutively on the same electron route. This describes the normal architecture of oxidative phosphorylation.

The dehydrogenase complexes that lipoic acid serves finish each cycle by reducing NAD to NADH through their flavoprotein E3 subunit. The lipoyl arm and the NAD acceptor are both required for the complex to turn over. Neither can substitute for the other.

Glutathione reductase spends NADPH to return oxidised glutathione to its reduced form, and that NADPH comes from the NADP pool built on niacinamide. The recycling step is the reason a given pool of glutathione can act repeatedly. This is settled redox biochemistry.

N-acetylcysteine provides cysteine, the rate-limiting residue for glutathione synthesis, while the NADP-derived reducing power keeps that glutathione in its active state. One supplies the molecule, the other keeps resetting it. The two act on separate halves of the same cycle.

Thioredoxin reductase and the glutathione peroxidases are selenoenzymes whose catalytic cycles are completed by NADPH-driven reduction. Niacinamide supplies the nucleotide backbone of that reducing power. The dependency is structural to the enzymes.

NAD kinase uses ATP to phosphorylate NAD into NADP, and ATP functions as a magnesium complex in that and every other kinase reaction. Magnesium status therefore sits behind the size of the NADP pool. This is textbook enzymology.

NAD synthetase completes NAD assembly by transferring an amide nitrogen, and glutamine is the physiological donor for that transfer in mammals. Glutamine is therefore part of the machinery that finishes the molecule. The link is biochemical rather than a tested pairing.

Nicotinamide is salvaged into NAD by nicotinamide phosphoribosyltransferase, which attaches it to phosphoribosyl pyrophosphate. That donor derives from the ribose-5-phosphate pool. Ribose availability sits upstream of the salvage step rather than acting on it directly.

Electrons that enter the respiratory chain as NADH are handed off at the end to cytochrome c oxidase, a copper-dependent complex. Copper status governs that terminal step while niacinamide governs the entry point. Both are needed for the chain to carry flux.

A large family of zinc metalloenzymes, including the alcohol and aldehyde dehydrogenases, uses NAD as its electron acceptor. Zinc holds the catalytic site and niacinamide supplies the cosubstrate. In topical formulation the two are also combined by convention.

Nicotinamide N-methyltransferase clears surplus nicotinamide by spending an S-adenosylmethionine methyl group on each molecule, and choline via betaine is one of the routes that regenerates the methyl pool. Sustained high nicotinamide intake is therefore a draw on methyl supply. The direction here is competition, which is exactly why methyl donors are formulated alongside high-dose NAD precursors.

S-adenosylmethionine is generated from methionine and consumed by nicotinamide methylation. High niacinamide intakes compete with every other methyltransferase reaction for the same donor. Read the interaction as a demand on methionine rather than a combined benefit.

Glycine N-methyltransferase is the principal buffer for excess S-adenosylmethionine, and nicotinamide methylation draws on the same pool. The two reactions share one currency and one regulatory set point. This is competition for methyl groups, described at the enzyme level.

Niacinamide and ascorbic acid are routinely combined in topical formulas, and the old objection that they cannot coexist came from heat-driven conversion of niacinamide to nicotinic acid rather than from ordinary use. Modern formulation handles this through pH control and stabilised ascorbate derivatives. The pairing is formulation convention supported by stability work, not a clinical combination finding.

Hyaluronic acid is a humectant vehicle component rather than an active partner, holding water at the skin surface while niacinamide is delivered from the same base. The two do not interact chemically. This is vehicle design and it is worth labelling as such rather than as a synergy of actives.